Eyegate Pharmaceuticals Inc (NASDAQ:EYEG)’s share price fell 3.8% during mid-day trading on Thursday . The company traded as low as $2.01 and last traded at $2.02, with a volume of 64,557 shares. The stock had previously closed at $2.10.

A number of research firms recently issued reports on EYEG. Rodman & Renshaw reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a research note on Thursday, May 12th. Maxim Group reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a research note on Tuesday, April 26th. Chardan Capital reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a research note on Thursday, April 14th. Finally, Noble Financial began coverage on shares of Eyegate Pharmaceuticals in a research note on Thursday, April 7th. They issued a “buy” rating and a $10.00 price target for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Eyegate Pharmaceuticals presently has an average rating of “Buy” and an average target price of $9.00.

The firm’s market capitalization is $18.11 million. The firm’s 50-day moving average price is $2.53 and its 200 day moving average price is $2.99.

In other news, Director Morton Goldberg sold 15,000 shares of the business’s stock in a transaction dated Wednesday, June 15th. The shares were sold at an average price of $3.16, for a total value of $47,400.00. Following the sale, the director now directly owns 17,277 shares in the company, valued at approximately $54,595.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Ventech Capital Ii sold 29,400 shares of the business’s stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $3.25, for a total transaction of $95,550.00. Following the completion of the sale, the insider now owns 1,641,540 shares in the company, valued at $5,335,005. The disclosure for this sale can be found here.

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.